Coronavirus-19 disease (COVID-19) affects more people than previous coronavirus infections and has a higher mortality. Higher incidence and mortality can probably be explained by COVID-19 causative agent's greater affinity (about 10-20 times) for angiotensin-converting enzyme 2 (ACE2) receptor compared with other coronaviruses. Here, the authors first summarize clinical manifestations, then present symptoms of COVID-19 and the pathophysiological mechanisms underlying specific organ/system disease. The worse clinical outcome observed in COVID-19 patients with diabetes may be in part related to the increased ADAM17 activity and its unbalanced interplay with ACE2. Therefore, strategies aimed to inhibit ADAM17 activity may be explored to develop new effective therapeutic approaches.

COVID-19–Associated Endothelial Dysfunction and Microvascular Injury. From Pathophysiology to Clinical Manifestations / Canale, M. P.; Menghini, R.; Martelli, E.; Federici, M.. - 14:1(2022), pp. 21-28. [10.1016/j.ccep.2021.10.003]

COVID-19–Associated Endothelial Dysfunction and Microvascular Injury. From Pathophysiology to Clinical Manifestations

Menghini R.;Martelli E.;
2022

Abstract

Coronavirus-19 disease (COVID-19) affects more people than previous coronavirus infections and has a higher mortality. Higher incidence and mortality can probably be explained by COVID-19 causative agent's greater affinity (about 10-20 times) for angiotensin-converting enzyme 2 (ACE2) receptor compared with other coronaviruses. Here, the authors first summarize clinical manifestations, then present symptoms of COVID-19 and the pathophysiological mechanisms underlying specific organ/system disease. The worse clinical outcome observed in COVID-19 patients with diabetes may be in part related to the increased ADAM17 activity and its unbalanced interplay with ACE2. Therefore, strategies aimed to inhibit ADAM17 activity may be explored to develop new effective therapeutic approaches.
2022
ACE2; ADAM17; covid-19 clinical manifestations; endothelial dysfunction; systemic inflammation; humans; SARS-CoV-2; covid-19; vascular diseases
01 Pubblicazione su rivista::01m Editorial/Introduzione in rivista
COVID-19–Associated Endothelial Dysfunction and Microvascular Injury. From Pathophysiology to Clinical Manifestations / Canale, M. P.; Menghini, R.; Martelli, E.; Federici, M.. - 14:1(2022), pp. 21-28. [10.1016/j.ccep.2021.10.003]
File allegati a questo prodotto
File Dimensione Formato  
Canale_COVID-19-Associated-Endothelial_2022.pdf

solo gestori archivio

Note: pdf pubblicato
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 214.64 kB
Formato Adobe PDF
214.64 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1666200
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 6
  • ???jsp.display-item.citation.isi??? ND
social impact